/ABSI
ABSI Stock - Absci Corporation
Healthcare|BiotechnologyNASDAQ
$3.38-0.88%
$0.03 (-0.88%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.54
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.34
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+136.7%upside
Target: $8.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ABSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.35 – $3.41
TARGET (TP)$8.00
STOP LOSS$3.11
RISK/REWARD1:17.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.14
52W High$6.33
52W Low$2.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.53M | $5.72M | $5.75M | $4.78M | $4.78M |
| Gross Profit | $-57,925,000 | $-41,849,000 | $-53,161,000 | $-39,804,000 | $-6,668,000 |
| Gross Margin | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% |
| Operating Income | $-108,888,000 | $-115,515,000 | $-106,750,000 | $-75,238,000 | $-13,301,000 |
| Net Income | $-103,106,000 | $-110,566,000 | $-104,904,000 | $-100,960,000 | $-14,353,000 |
| Net Margin | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% |
| EPS | $-0.94 | $-1.20 | $-1.15 | $-1.11 | $-0.54 |
Company Overview
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 125.6% Upside
Now
$3
Low
$8
Average
$13
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 2nd 2025 | JP Morgan | Initiation | Overweight | - |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $7 |
| January 22nd 2025 | Needham | Initiation | Buy | $9 |
| October 2nd 2024 | Guggenheim | Initiation | Buy | $10 |
| July 3rd 2024 | Morgan Stanley | Initiation | Overweight | $7 |
| March 14th 2024 | Scotiabank | Initiation | Sector Outperform | $13 |
| December 5th 2023 | KeyBanc Capital Markets | Initiation | Overweight | $3 |
| May 4th 2023 | H.C. Wainwright | Initiation | Buy | $4 |
| August 12th 2022 | JP Morgan | Downgrade | Underweight | - |
| July 18th 2022 | Truist | Initiation | Buy | $8 |
Earnings History & Surprises
ABSIBeat Rate
11%
Last 18 quarters
Avg Surprise
-20.9%
EPS vs Estimate
Beats / Misses
2/15
1 met exactly
Latest EPS
$-0.20
Q4 2025
EPS Surprise History
Q1 24
-8.7%
$-0.25vs$-0.23
Q2 24
-15.8%
$-0.22vs$-0.19
Q3 24
-15.8%
$-0.22vs$-0.19
Q4 24
-26.3%
$-0.24vs$-0.19
Q1 25
-13.6%
$-0.25vs$-0.22
Q2 25
+8.7%
$-0.21vs$-0.23
Q3 25
-26.3%
$-0.24vs$-0.19
Q4 25
-5.3%
$-0.20vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 17, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.27 | $-0.30 | -11.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.32 | $-0.32 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.21 | $-0.28 | -33.3% | ✗ MISS |
Q3 2021 | Sep 7, 2021 | $-0.85 | $-2.39 | -181.2% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Absci, Raises Price Target to $8
📈 PositiveBenzinga•Dec 18, 2025, 09:59 AM
Needham Reiterates Buy on Absci, Maintains $7 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 11:41 AM
Absci Unveils Preclinical Data Showing AI‑Designed Antibody ABS‑201 Stimulates Hair Growth; Findings Presented At ABS‑201 KOL Seminar
📈 PositiveBenzinga•Dec 11, 2025, 01:15 PM
Absci shares are trading higher after the company announced the first healthy volunteers have been dosed in the Phase 1/2a HEADLINE study evaluating ABS-201.
📈 PositiveBenzinga•Dec 4, 2025, 04:19 PM
Absci Doses Participants In Phase 1/2a HEADLINE Trial Of ABS-201
➖ NeutralBenzinga•Dec 4, 2025, 01:07 PM
Absci shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 01:53 PM
Needham Maintains Buy on Absci, Lowers Price Target to $7
📈 PositiveBenzinga•Nov 13, 2025, 10:46 AM
Absci shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 09:17 PM
Absci Q3 EPS $(0.20) Beats $(0.21) Estimate, Sales $378.000K Miss $1.644M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 09:09 PM
Absci climbs on clinical trial acceleration
📈 PositiveSeeking Alpha•Oct 15, 2025, 03:31 PM
Absci To Host December 11 Seminar On ABS-201 For Androgenetic Alopecia; Phase 1/2a Trial Now Expected To Begin In December, Ahead Of Prior Guidance
📈 PositiveBenzinga•Oct 15, 2025, 12:08 PM
Absci spikes as J.P. Morgan starts at Buy ahead of key catalyst
📈 PositiveSeeking Alpha•Oct 2, 2025, 06:19 PM
Absci shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating.
📈 PositiveBenzinga•Oct 2, 2025, 01:25 PM•Also:
JP Morgan Initiates Coverage On Absci with Overweight Rating
📈 PositiveBenzinga•Oct 2, 2025, 11:18 AM•Also:
Absci shares are trading higher after the company announced it will use Oracle Cloud Infrastructure and AMD hardware for AI-driven drug discovery.
📈 PositiveBenzinga•Sep 11, 2025, 12:03 PM•Also: ,
Absci To Utilize Oracle Cloud Infrastructure And AMD Hardware For AI-Driven Drug Discovery
📈 PositiveBenzinga•Sep 11, 2025, 12:01 PM•Also: ,
Morgan Stanley Maintains Overweight on Absci, Lowers Price Target to $5.89
➖ NeutralBenzinga•Aug 18, 2025, 12:59 PM
Absci Sales Fall 54 Percent
📉 NegativeThe Motley Fool•Aug 13, 2025, 02:08 AM
Absci stock dips after pricing $50M offering
📉 NegativeSeeking Alpha•Jul 25, 2025, 06:47 AM
Absci announces proposed public offering of common stock
➖ NeutralSeeking Alpha•Jul 24, 2025, 08:58 PM
Frequently Asked Questions about ABSI
What is ABSI's current stock price?
Absci Corporation (ABSI) is currently trading at $3.38 per share. The stock has moved -0.88% today.
What is the analyst price target for ABSI?
The average analyst price target for ABSI is $8.00, based on 1 analyst.
What sector is Absci Corporation in?
Absci Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ABSI's market cap?
Absci Corporation has a market capitalization of $0.51 billion, making it a small-cap company.
Does ABSI pay dividends?
No, Absci Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
PRTA
Prothena Corporation plc
$9.21
Mkt Cap: $0.5B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to ABSI for comparison